Cell line · CVCL_1824
KG-1a
Cancer cell line, Homo sapiens. Acute myeloid leukemia without maturation. 24 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. KG-1a. Cell lines, record CVCL_1824. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1824
On this page
Cell line
As Cellosaurus gives it.
- Name
- KG-1a
- Accession
- CVCL_1824
- RRID
- RRID:CVCL_1824
- Synonyms
- KG-1A, KG1A, KG1a
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 59Y
- Category
- Cancer cell line
- Diseases
- Acute myeloid leukemia without maturation (NCIt C3249); Adult acute myeloid leukemia (NCIt C9154); Acute myeloid leukemia (ORDO Orphanet_519)
- Derived from
- Bone marrow (in situ)
- Parent
- KG-1 (CVCL_0374)
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers24
4 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Dynamic Switching of Apoptosis-Modulating Bim Heterodimers in Response to BH3 Mimetics in Xenograft Models of Hematologic Malignancies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia. | FEBS J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. | Int J Mol Sci | 2023 | Cellosaurus cites it | PubMed |
1 to 10 of 24
See all 24 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Parent | KG-1 | CVCL_0374 |
Source Cell lines
Cell banks10
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CCL-246.1 | ATCC | |
| BCRC | 60224 | BCRC | |
| CLS | 300234 | CLS | |
| DSMZ | ACC-421 | DSMZ | |
| ECACC | 91030101 | ECACC | |
| IZSLER | BS TCL 196 | Cellosaurus | |
| NCBI_Iran | C520 | Cellosaurus | |
| RCB | RCB1928 | RCB | |
| TKG | TKG 0402 | Cellosaurus | |
| Ubigene | YC-C083 | Ubigene |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1824
GET https://conductscience.org/api/cell-lines/v1/CVCL_1824/papers?page=2